Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BOTOPEP is a topical anti-aging product line developed by La Pristine Bioceuticals, available as both a serum and a cream. It is formulated with "Botox-like" peptides, most notably **acetyl hexapeptide-8** (also known as Argireline). These peptides are designed to reduce the appearance of fine lines and wrinkles by modulating the release of neurotransmitters at the neuromuscular junction. Specifically, acetyl hexapeptide-8 mimics a component of the SNARE complex, competing for a position and thereby inhibiting the docking of vesicles containing neurotransmitters like acetylcholine. This action leads to a localized relaxation of facial muscles, smoothing expression lines without the need for invasive injections. BOTOPEP is marketed within the company's dermatology portfolio for anti-aging and skin rejuvenation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BOTOPEP.